Cationic antimicrobial peptides are produced by almost all species of life as a component of
their immediate non-specific defense against infections. The assets of these peptides in
clinical application include their potential for broad-spectrum activity, rapid bactericidal
activity and low propensity for resistance development, whereas possible disadvantages
include their high cost, limited stability (especially when composed of L-amino acids), and
unknown toxicology and pharmacokinetics. Initial barriers to their success are being …